Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Accounts Payables (2019 - 2026)

Alx Oncology Holdings' Accounts Payables history spans 5 years, with the latest figure at $8.6 million for Q4 2023.

  • On a quarterly basis, Accounts Payables rose 6.42% to $8.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $8.6 million, a 6.42% increase, with the full-year FY2023 number at $8.6 million, up 6.42% from a year prior.
  • Accounts Payables hit $8.6 million in Q4 2023 for Alx Oncology Holdings, down from $13.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for ALXO hit a ceiling of $13.0 million in Q3 2023 and a floor of $4000.0 in Q4 2020.
  • Historically, Accounts Payables has averaged $5.7 million across 5 years, with a median of $5.5 million in 2021.
  • Biggest five-year swings in Accounts Payables: plummeted 99.89% in 2020 and later skyrocketed 94000.0% in 2021.
  • Tracing ALXO's Accounts Payables over 5 years: stood at $3.7 million in 2019, then plummeted by 99.89% to $4000.0 in 2020, then skyrocketed by 94000.0% to $3.8 million in 2021, then skyrocketed by 114.48% to $8.1 million in 2022, then grew by 6.42% to $8.6 million in 2023.
  • Business Quant data shows Accounts Payables for ALXO at $8.6 million in Q4 2023, $13.0 million in Q3 2023, and $4.1 million in Q2 2023.